Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XELOX + SOX
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Fudan University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
XELOX + SOX is a combination chemotherapy regimen being investigated in the ROSETTE trial for the treatment of limited-metastatic gastric or gastroesophageal junction adenocarcinoma. This regimen combines the components of two standard chemotherapy protocols: XELOX (oxaliplatin and capecitabine) and SOX (oxaliplatin and S-1), effectively utilizing oxaliplatin, capecitabine, and the multi-component agent S-1 (a combination of tegafur, gimeracil, and oteracil). Oxaliplatin functions as a DNA-alkylating agent that induces cross-links, while capecitabine and S-1 are fluoropyrimidine prodrugs that inhibit thymidylate synthase, thereby disrupting DNA synthesis. Developed and studied by Shanghai Zhongshan Hospital, this intensive cytotoxic backbone is often paired with immunotherapy (PD-1 antibodies) and targeted therapies (such as trastuzumab or zolbetuximab) to maximize pathological response before surgery-centric local treatments.
- Other names
- XELOX/SOXOxaliplatin + Capecitabine + S-1XELOX + SOX-Shanghai Zhongshan Hospital-gastric adenocarcinoma-gastroesophageal junction adenocarcinoma
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)OPRT (Orotidine 5'-phosphate decarboxylase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on XELOX + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XELOX + SOX.